Cyto-reduction of neuroendocrine tumours using Sandostatin LAR® in combination with Infergen®: Results of a case series

Journal of Pharmacy and Pharmacology

Volumn 58, Issue 12, 2006, Pages 1623-1628

  Wang, Hank S ^a   Oh, David S ^a,b   Ohning, Gordon V ^a,b   Pisegna, Joseph R ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CONSENSUS INTERFERON; OCTREOTIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; MALE; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIOGRAPHY; TREATMENT RESPONSE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTHRALGIA; CELL GROWTH PROCESSES; CHROMOGRANIN A; COMBINED MODALITY THERAPY; DIARRHEA; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTRINS; HEADACHE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PATIENT DROPOUTS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 33846031591     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.58.12.0009     Document Type: Article

References (33)

1. Aparicio, T., Ducreux, M., Baudin, E., Sabourin, J. C., De Baere, T., Mitry, E., Schlumberger, M., Rougier, P. (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur. J. Cancer. 37: 1014-1019
2. Arnold, R., Rinke, A., Klose, K. J., Muller, H. H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Moll, R., Koller, M., Unterhalt, M., Hiddemann, W., Schmidt-Lauber, M., Pavel, M., Arnold, C. N. (2005) Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol. 3: 761-771
3. Caplin, M. E., Hodgson, H. J., Dhillon, A. P., Begent, R., Buscombe, J., Dick, R., Rolles, K., Burroughs, A. K. (1998) Multimodality treatment for gastric carcinoid tumor with liver metastases. Am. J. Gastroenterol. 93: 1945-1948
4. Chung, M. H., Pisegna, J., Spirt, M., Giuliano, A. E., Ye, W., Ramming, K. P., Bilchik, A. J. (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130: 954-962
5. Clouse, M. E., Perry, L., Stuart, K., Stokes, K. R. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55: 92-97
6. Delesque, N., Buscail, L., Esteve, J. P., Saint-Laurent, N., Muller, C., Weckbecker, G., Bruns, C., Vaysse, N., Susini, C. (1997) sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57: 956-962
7. Denzler, B., Reubi, J. C. (1999) Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85: 188-198
8. Ducreux, M., Ruszniewski, P., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., Raymond, J. M., Dupas, J. L., Gouerou, H., Jian, R., Genestin, E., Hammel, P., Rougier, P. (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am. J. Gastroenterol. 95: 3276-3281
9. Faiss, S., Pape, U. F., Bohmig, M., Dorffel, Y., Mansmann, U., Golder, W., Riecken, E. O., Wiedenmann, B. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 21: 2689-2696
10. Fjallskog, M. L., Sundin, A., Westlin, J. E., Oberg, K., Janson, E. T., Eriksson, B. (2002) Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med. Oncol. 19: 35-42
11. Frank, M., Klose, K. J., Wied, M., Ishaque, N., Schade-Brittinger, C, Arnold, R. (1999) Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am. J. Gastroenterol. 94: 1381-1387
12. Goebel, S. U., Serrano, J., Yu, F., Gibril, F., Venzon, D. J., Jensen, R. T. (1999) Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85: 1470-1483
13. Grander, D., Sangfelt, O., Erickson, S. (1997) How does interferon exert its cell growth inhibitory effect? Eur. J. Haematol. 59: 129-135
14. Hobeika, A. C., Subramaniam, P. S., Johnson, H. M. (1997) IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14: 1165-1170
15. Jacobsen, M. B., Hanssen, L. E., Kolmannskog, F., Schrumpf, E., Vatn, M. H., Bergan, A. (1995) Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian Carcinoid Study. Scand. J. Gastroenterol. 30: 789-796
16. Jensen, R. T. (1999) Natural history of digestive endocrine tumors. In: Mignon, M., Colombel, J. F. (eds) Recent advances in pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors. John Libbey Eurotext Publishing Co., Paris, pp 192-219
17. Kaltsas, G. A., Besser, G. M., Grossman, A. B. (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev. 25: 458-511
18. Kolby, L., Persson, G., Franzen, S., Ahren, B. (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. 90: 687-693
19. Lamberts, S. W., van der Lely, A. J., de Herder, W. W., Hofland, L. J. (1996) Octreotide. N. Engl. J. Med. 334: 246-254
20. Moertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., Klaassen, D. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl J. Med. 326: 519-523
21. Oberg, K. (1998) Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist 3: 339-345
22. Oberg, K. (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62: 92-97
23. Oberg, K., Funa, K., Aim, G. (1983) Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N. Engl J. Med. 309: 129-133
24. Pisegna, J. R., Doppman, J. L., Norton, J. A., Metz, D. C., Jensen, R. T. (1993a) Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig. Dis. Sci. 38: 1318-1328
25. Pisegna, J. R., Slimak, G. G., Doppman, J. L., Strader, D. B., Metz, D. C., Benya, R. V., Orbuch, M., Fishbeyn, V. A., Fraker, D. L., Norton, J. A. (1993b) An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 105: 1179-1183
26. Proye, C. A., Lokey, J. S. (2004) Current concepts in functioning endocrine tumors of the pancreas. World J. Surg. 28: 1231-1238
27. Reubi, J. C., Schaer, J. C., Laissue, J. A., Waser, B. (1996) Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45: 39-41
28. Ricci, S., Antonuzzo, A., Galli, L., Ferdeghini, M., Bodei, L., Orlandini, C., Conte, P. F. (2000) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann. Oncol. 11: 1127-1130
29. Rubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., Anthony, L. (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. 17: 600-606
30. Tomassetti, P., Migliori, M., Corinaldesi, R., Gullo, L. (2000) Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment. Pharmacol. Ther. 14: 557-560
31. Welin, S. V., Janson, E. T., Sundin, A., Stridsberg, M., Lavenius, E., Granberg, D., Skogseid, B., Oberg, K. E., Eriksson, B. K. (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol. 151: 107-112
32. Wymenga, A. N., Eriksson, B., Salmela, P. I., Jacobsen, M. B., Van Cutsem, E. J., Fiasse, R. H., Valimaki, M. J., Renstrup, J., de Vries, E. G., Oberg, K. E. (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J. Clin. Oncol. 17: 1111
33. Zhou, Y., Wang, S., Gobi, A., Oberg, K. (1999) Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells. J. Biol. Regul. Homeost. Agents 13: 207-215